The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps
Status | Suspended |
Decision | Selected |
Process | TAG |
ID number | 1413 |
Timeline
Key events during the development of the guidance:
Date | Update |
---|---|
09 March 2020 | The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of paclitaxel as albumin-bound nanoparticles with gemcitabine for adjuvant treatment of pancreatic cancer [ID1413]. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
25 January 2019 | Suspended. The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps |
22 July 2016 | In progress. Topic referred |
For further information on our processes and methods, please see our CHTE processes and methods manual